Detalhe da pesquisa
1.
Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
Br J Haematol
; 199(3): 366-370, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35892294
2.
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 848-857, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34000246
3.
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
J Immunother Cancer
; 12(3)2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38519055
4.
Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma.
Nat Med
; 29(6): 1389-1399, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37322116
5.
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.
Sci Transl Med
; 14(670): eabn1082, 2022 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36350988
6.
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
Lancet Gastroenterol Hepatol
; 7(3): 219-229, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35065058